[
  {
    "ts": "2026-02-18T09:35:00+00:00",
    "headline": "Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash",
    "summary": "Vertex has the revenue power to excel during any market environment.",
    "url": "https://www.fool.com/investing/2026/02/18/vertex-the-biotech-compounder-id-happily-hold/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "728d58a4-c3df-3d35-acc6-d439910c4e1f",
      "content": {
        "id": "728d58a4-c3df-3d35-acc6-d439910c4e1f",
        "contentType": "STORY",
        "title": "Vertex: The Quiet Biotech Compounder I'd Happily Hold Through Any Market Crash",
        "description": "",
        "summary": "Vertex has the revenue power to excel during any market environment.",
        "pubDate": "2026-02-18T09:35:00Z",
        "displayTime": "2026-02-18T09:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/e36e1ec4d1c929e02151a3c3a57064ab",
          "originalWidth": 1400,
          "originalHeight": 738,
          "caption": "Researchers smile in a lab setting.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/z9UMtclM_3qSy09XlJ3Ffg--~B/aD03Mzg7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/e36e1ec4d1c929e02151a3c3a57064ab.cf.webp",
              "width": 1400,
              "height": 738,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G6v5uH2_.28s7DSB33AwMQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/e36e1ec4d1c929e02151a3c3a57064ab.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/18/vertex-the-biotech-compounder-id-happily-hold/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-quiet-biotech-compounder-id-093500445.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T15:13:00+00:00",
    "headline": "Should You Buy Shares of CRISPR Therapeutics in February?",
    "summary": "The company could finally be ready to deliver on years of promise.",
    "url": "https://www.fool.com/investing/2026/02/18/should-you-buy-crispr-therapeutics-in-february/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "45378181-1d48-3420-b527-70d4698bbf4f",
      "content": {
        "id": "45378181-1d48-3420-b527-70d4698bbf4f",
        "contentType": "STORY",
        "title": "Should You Buy Shares of CRISPR Therapeutics in February?",
        "description": "",
        "summary": "The company could finally be ready to deliver on years of promise.",
        "pubDate": "2026-02-18T15:13:00Z",
        "displayTime": "2026-02-18T15:13:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4118074f06f1c5afa87063b95f68103e",
          "originalWidth": 1400,
          "originalHeight": 934,
          "caption": "CRISPR Therapeutics logo on a phone and backdrop.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PsGiiZowdbfXhSfONm8ncg--~B/aD05MzQ7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4118074f06f1c5afa87063b95f68103e.cf.webp",
              "width": 1400,
              "height": 934,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QDtu95pqvfSmhYPPWFPTfQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4118074f06f1c5afa87063b95f68103e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/18/should-you-buy-crispr-therapeutics-in-february/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-shares-crispr-therapeutics-february-151300066.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]